{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-25-000081","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.145476+00:00","generated_at":"2026-05-17T16:03:03.397662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI Pharma Q2 record revenues $211.4M, EPS $0.36; lifts FY guidance","bullets":["Q2 net revenue $211.4M (+53.1% YoY); GAAP EPS $0.36 vs ($0.14); record adjusted EBITDA $54.1M (+62.8%).","Rare Disease rev $104.0M (Cortrophin Gel $81.6M, +66%; ILUVIEN/YUTIQ $22.3M).","Generics rev $90.3M (+22.1%); driven by new launches including first-to-market prucalopride.","Raised FY2025 guidance: rev $818M–$843M; adj EBITDA $213M–$223M; adj EPS $6.98–$7.35.","Cash & equivalents $217.8M; year-to-date CFO $110.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-25-000081","json":"https://secwatch.observer/filing/0001023024-25-000081.json","markdown":"https://secwatch.observer/filing/0001023024-25-000081.md","text":"https://secwatch.observer/filing/0001023024-25-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/0001023024-25-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/ani-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:03:03.397662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}